Consolidated income statement For the year ended 31 December 2018 2018 2017 Exceptional Exceptional 2018 items and other 2018 2017 items and other 2017 Core adjustments Reported Core adjustments Reported results note 6 results results note 6 results Note $m $m $m $m $m $m Revenue 4 2,076 6 2,070 1,936 1,936 Cost of sales 1,004 16 1,020 963 6 969 Gross profit 1,072 22 1,050 973 6 967 Sales and marketing expenses 191 33 224 188 48 236 General and administrative expenses 246 246 238 1 239 Net impairment reversals on financial assets 11 11 Research and development expenses 118 29 147 115 6 121 Other operating expenses net 9 68 5 73 46 1,072 1,118 Total operating expenses 612 67 679 587 1,127 1,714 Operating profit loss 5 460 89 371 386 1,133 747 Finance income 10 3 3 2 93 95 Finance expense 11 54 26 80 60 26 86 Loss from investment at fair value 1 1 Profit loss before tax 408 115 293 328 1,066 738 Tax 12 73 65 8 72 29 101 Profit loss for the year 335 50 285 256 1,095 839 Attributable to: Non-controlling interests 34 3 3 4 4 Equity holders of the parent 332 50 282 252 1,095 843 335 50 285 256 1,095 839 Earnings loss per share cents Basic 15 137.8 117.0 105.0 351.3 Diluted 15 137.2 116.5 104.6 349.8 116 Hikma Pharmaceuticals PLC | Annual Report 2018 116 Financial statements Consolidated statement of comprehensive income For the year ended 31 December 2018 2018 2017 Exceptional Exceptional 2018 items and other 2018 2017 items and other 2017 Core adjustments Reported Core adjustments Reported results note 6 results results note 6 results Note $m $m $m $m $m $m Profit loss for the year 335 50 285 256 1,095 839 Other comprehensive income loss Items that may be reclassified subsequently to the consolidated income statement, net of tax: Currency translation loss gain 29 29 20 20 Items that will not be reclassified subsequently to the consolidated income statement, net of tax: Change in fair value of available-for-sale financial assets 24 2 2 Change in the fair value of equity investments 19 7 7 Total comprehensive income loss for the year 313 50 263 278 1,095 817 Attributable to: Non-controlling interests 1 1 3 3 Equity holders of the parent 312 50 262 275 1,095 820 313 50 263 278 1,095 817 1.
This investment was previously designated as available-for-sale financial assets, upon transition to IFRS 9 it has been re-categorised as Investments measured at fair value through profit or loss FVTPL 2.
This investment was previously classified as available-for-sale and stated at cost under IAS 39 cost exemption : upon transition to IFRS 9 it has been re-categorised as Investments measured at fair value through other comprehensive income FVTOCI 117 Hikma Pharmaceuticals PLC | Annual Report 2018 117 Consolidated balance sheet At 31 December 2018 2018 2017 Note $m $m Non-current assets Goodwill 16 279 282 Other intangible assets 16 487 503 Property, plant and equipment 17 870 828 Investment in associates and joint ventures 18 11 6 Deferred tax assets 13 125 135 Financial and other non-current assets 19 57 60 1,829 1,814 Current assets Inventories 20 528 488 Income tax receivable 74 53 Trade and other receivables 21 731 707 Collateralised and restricted cash 22 4 Cash and cash equivalents 23 276 227 Other current assets 24 59 95 1,668 1,574 Total assets 3,497 3,388 Current liabilities Bank overdrafts and loans 25 74 86 Trade and other payables 26 465 365 Income tax provision 68 82 Other provisions 27 23 26 Other current liabilities 28 263 238 893 797 Net current assets 775 777 Non-current liabilities Long-term financial debts 29 539 670 Obligations under finance leases 30 23 20 Deferred tax liabilities 13 16 49 Other non-current liabilities 32 329 324 907 1,063 Total liabilities 1,800 1,860 Net assets 1,697 1,528 Equity Share capital 33 40 40 Share premium 282 282 Other reserves 217 190 Retained earnings 1,580 1,382 Equity attributable to equity holders of the parent 1,685 1,514 Non-controlling interests 34 12 14 Total equity 1,697 1,528 The consolidated financial statements of Hikma Pharmaceuticals PLC, registered number 5557934, on pages 116 to 167 were approved by the Board of Directors on 12 March 2019 and signed on its behalf by: Said Darwazah Sigurdur Olafsson Director Director 12 March 2019 118 Hikma Pharmaceuticals PLC | Annual Report 2018 118 Financial statements Consolidated statement of changes in equity For the year ended 31 December 2018 Equity attributable Merger and to equity Nonrevaluation Translation Total other Retained Share Share shareholders controlling Total reserves reserve Own shares reserves earnings capital premium of the parent interests equity $m $m $m $m $m $m $m $m $m $m Balance at 1 January 2017 1,077 248 1 828 1,246 40 282 2,396 15 2,411 1 Loss for the year 1,039 1,039 196 843 4 839 Change in fair value of available-for- 2 sale financial assets note 24 1 1 1 Currency translation gain loss 21 21 21 1 20 Total comprehensive loss income for the year 1,039 21 1,018 197 821 3 818 Cost of equity-settled employee share scheme note 38 22 22 22 Dividends on ordinary shares note 14 79 79 2 81 Adjustment arising from change in non-controlling interests note 34 4 4 2 6 Total transactions with owners, recognised directly in equity Balance at 31 December 2017 and 1 January 2018 as previously reported 38 227 1 190 1,382 40 282 1,514 14 1,528 3 Impact of IFRS 9 3 3 3 3 Impact of IFRS 15 25 25 25 Balance at 1 January 2018 as adjusted 38 227 1 190 1,354 40 282 1,486 14 1,500 Profit for the year 282 282 3 285 Change in the fair value of equity investments at fair value through other 4 comprehensive income note 19 7 7 7 Currency translation loss 27 27 27 2 29 Total comprehensive income loss for the year 27 27 289 262 1 263 Total transactions with owners, recognised directly in equity Cost of equity-settled employee share scheme note 38 21 21 21 Dividends on ordinary shares note 14 84 84 3 87 Balance at 31 December 2018 38 254 1 217 1,580 40 282 1,685 12 1,697 1.
In 2017 a loss of $1,039 million had been allocated from retained earnings to the merger and revaluation reserves in relation to the Columbus business impairment note 6, 16 and 17 2.
This investment was previously designated as available-for-sale financial assets, upon transition to IFRS 9 it has been re-categorised as Investments FVTPL 3.
The Group adopted IFRS 9 and IFRS 15 from 1 January 2018 note 1, 4, 28 and 44 4.
This investment was previously classified as available-for-sale and stated at cost under IAS 39 cost exemption : upon transition to IFRS 9 it has been re-categorised as Investments at FVTOCI 119 Hikma Pharmaceuticals PLC | Annual Report 2018 119 Consolidated cash flow statement For the year ended 31 December 2018 2018 2017 Note $m $m Cash flows from operating activities Cash generated from operations 36 493 546 Income taxes paid 63 103 Net cash inflow from operating activities 430 443 Cash flow from investing activities Purchases of property, plant and equipment 107 107 Proceeds from disposal of property, plant and equipment 13 4 Purchase of intangible assets 32 44 Cash paid received from investment in joint ventures 4 2 Investment in financial and other non-current assets, net 4 2 Investments at fair value through other comprehensive income 2017: available-for-sale investment 4 8 Acquisition of business undertakings net of cash acquired 1 3 Contingent consideration adjustment 30 Finance income 3 1 Net cash outflow from investing activities 96 151 Cash flow from financing activities Decrease in collateralised and restricted cash 3 3 Proceeds from issue of long-term financial debts 93 349 Repayment of long-term financial debts 224 401 Proceeds from short-term borrowings 138 323 Repayment of short-term borrowings 148 349 Dividends paid 84 79 Dividends paid to non-controlling shareholders of subsidiaries 3 2 Interest paid 51 57 Purchase of non-controlling interest in subsidiary 6 Payment from co-development and earnout payment agreement, net 2 1 Net cash outflow from financing activities 278 220 Net increase in cash and cash equivalents 56 72 Cash and cash equivalents at beginning of year 227 155 Foreign exchange translation movements 7 Cash and cash equivalents at end of year 276 227 1.
These cash flows relate to long-term financial debts note 29 and the movements above reconcile to the movement per the note.
In the prior year, the movement reconciled to the note after including a non-cash movement of $1 million in respect of unfavourable translation differences 2.
These cash flows relate to bank overdraft and loans note 25 and the movements above reconcile to the movement per the note after including a non-cash movement of $2 million 2017: $5 million in respect of favourable translation differences 120 Hikma Pharmaceuticals PLC | Annual Report 2018 120
